Reversed-phase HPLC methods for purity test and assay of pioglitazone hydrochloride in tablets

Pharmazie

Volumn 59, Issue 3, 2004, Pages 178-182

  Jedlička, Aleš ^a   Klimes J ^a   Grafnetterova T ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; BUFFER; FORMIC ACID; PIOGLITAZONE;

ARTICLE; ASSAY; DRUG DETERMINATION; DRUG PURITY; DRUG SCREENING; DRUG STRUCTURE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYPOGLYCEMIC AGENTS; MASS SPECTROMETRY; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; THIAZOLIDINEDIONES;

EID: 1642361403     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Castle CK, Colca JR, Melchior GW (1993) Lipoprotein profile characterisation of the KKA(Y) mouse, a rodent model of type-II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 13: 302-309.
2. Chen GL et al. (2000) The formulation design for pioglitazone rapid-release tablet. Chinese Pharm J 52: 295-303.
3. Hofmann CA, Edwards CW, Hillman RM, Colca JR (1992) Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone - evaluation of liver glut2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 130: 735-740.
4. Hofmann CA, Lorenz K, Colca JR (1991) Glucose-transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129: 1915-1925.
5. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T (1990) Effects of pioglitazone on glucose and lipid-metabolism in normal and insulin resistant animals. Arzneim.-Forsch 40: 156-162.
6. International conference on harmonisation of technical requirements of pharmaceuticals for human use (1994) Guideline Q2A: Text on Validation of Analytical Procedures.
7. International conference on harmonisation of technical requirements of pharmaceuticals for human use (1996) Guideline Q2B: Validation of Analytical Procedures: Methodology.
8. Kletzien RF, Clarke SD, Ulrich RG (1992) Enhacement of adipocyte differentiation by an insulin-senzitizing agent. Mol Pharmacol 41: 393-398.
9. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y (1992) Pioglitazone increases insulin senzitivity by activating insulin-receptor kinase. Diabetes 41: 476-483.
10. Radhakrishna T, Rao DS, Reddy GO (2002) Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods. J Pharm Biom Anal 29: 593-607.
11. Romanyshyn LA, Tiller PR (2001) Ultra-short columns and ballistic gradients: considerations for ultra-fast chromatographic liquid chromatographic-tandem mass spectrometric analysis. J Chromatogr A 928: 41-51.
12. Sohda T, Mizumo K, Momose Y, Ikeda H, Fujita T, Meguro K (1992) Studies on antidiabetic agents. 11. novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J Med Chem 35: 2617-2626.
13. Yamashita K, Murakami H, Okuda T, Motohashi M (1996) High-performance liquid chromatografic determination of pioglitazone and its metabolites in human serum and urine. J Chromatog. B 677: 141-146.
14. Zhong WZ, Lakings DB (1989) Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid-chromatography with ultraviolet (229 nm) detection. J Chromatogr Biomed Appl 490: 377-385.
15. Zhong WZ, Williams MG (1996) Simultaneous quantification of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J Pharm Biom Anal 14: 465-473.